CB7630
CB7630 is an orally active inhibitor of the steroidal enzyme 17 -hydroxylase/C17,20 lyase, a cytochrome p450 complex that is involved in testosterone production (see Figure below). In preclinical studies, CB7630 has demonstrated the ability to selectively inhibit the target enzyme, resulting in inhibition of testosterone production in both the adrenals and the testes.
In Phase I trials performed by Cancer Research UK, CB7630 was administered to 26 patients with prostate cancer. These clinical studies demonstrated that:1) CB7630 at a single oral dose of 800mg, can successfully suppress testosterone levels to the castrate range 2) CB7630 can suppress testosterone produced by both the testes and the adrenals 3) CB7630 is well tolerated and non-toxic.
Cougar is currently developing CB7630 (abiraterone acetate) as a second line hormonal therapy for prostate cancer for patients that are refractory to first line treatment with an LHRH agonist/antagonist and antiandrogen therapy.
|
|
|
